Literature DB >> 29912415

Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.

Michael Lattanzi1,2, Yesung Lee2,3, Danny Simpson2,4, Una Moran2,3, Farbod Darvishian2,5, Randie H Kim2,3, Eva Hernando2,5, David Polsky2,3,5, Doug Hanniford2,5, Richard Shapiro2,6, Russell Berman2,6, Anna C Pavlick1,2,3, Melissa A Wilson1,2, Tomas Kirchhoff2,4, Jeffrey S Weber1,2,3, Judy Zhong2,4, Iman Osman1,2,3.   

Abstract

BACKGROUND: Two primary histologic subtypes, superficial spreading melanoma (SSM) and nodular melanoma (NM), comprise the majority of all cutaneous melanomas. NM is associated with worse outcomes, which have been attributed to increased thickness at presentation, and it is widely expected that NM and SSM would exhibit similar behavior once metastasized. Herein, we tested the hypothesis that primary histologic subtype is an independent predictor of survival and may impact response to treatment in the metastatic setting.
METHODS: We examined the most recent Surveillance, Epidemiology, and End Results (SEER) cohort (n = 118 508) and the New York University (NYU) cohort (n = 1621) with available protocol-driven follow-up. Outcomes specified by primary histology were studied in both the primary and metastatic settings with respect to BRAF-targeted therapy and immunotherapy. We characterized known driver mutations and examined a 140-gene panel in a subset of NM and SSM cases using next-generation sequencing. All statistical tests were two-sided.
RESULTS: NM was an independent risk factor for death in both the SEER (hazard ratio [HR] = 1.55, 95% confidence interval [CI] = 1.41 to 1.70, P < .001) and NYU (HR = 1.47, 95% CI = 1.05, 2.07, P = .03) cohorts, controlling for thickness, ulceration, stage, and other variables. In the metastatic setting, NM remained an independent risk factor for death upon treatment with BRAF-targeted therapy (HR = 3.33, 95% CI = 1.06 to 10.47, P = .04) but showed no statistically significant difference with immune checkpoint inhibition. NM was associated with a higher rate of NRAS mutation (P < .001), and high-throughput sequencing revealed NM-specific genomic alterations in NOTCH4, ANK3, and ZNF560, which were independently validated.
CONCLUSIONS: Our data reveal distinct clinical and biological differences between NM and SSM that support revisiting the prognostic and predictive impact of primary histology subtype in the management of cutaneous melanoma.
© The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29912415      PMCID: PMC7962783          DOI: 10.1093/jnci/djy086

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  51 in total

1.  The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007.

Authors:  Waqas R Shaikh; Michael Xiong; Martin A Weinstock
Journal:  Arch Dermatol       Date:  2011-09-19

2.  Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.

Authors:  R L Barnhill; J A Fine; G C Roush; M Berwick
Journal:  Cancer       Date:  1996-08-01       Impact factor: 6.860

3.  Reprogramming of prostate cancer-associated stromal cells to embryonic stem-like.

Authors:  Eneida F Vêncio; Angelique M Nelson; Christopher Cavanaugh; Carol B Ware; Daniel G Milller; Julio C O Garcia; Ricardo Z N Vêncio; Michelle A Loprieno; Alvin Y Liu
Journal:  Prostate       Date:  2012-02-07       Impact factor: 4.104

4.  Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000.

Authors:  Susan M Swetter; Jennifer C Boldrick; Sandy Y Jung; Barbara M Egbert; Jeff D Harvell
Journal:  J Invest Dermatol       Date:  2005-10       Impact factor: 8.551

5.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

Authors:  Mahul B Amin; Frederick L Greene; Stephen B Edge; Carolyn C Compton; Jeffrey E Gershenwald; Robert K Brookland; Laura Meyer; Donna M Gress; David R Byrd; David P Winchester
Journal:  CA Cancer J Clin       Date:  2017-01-17       Impact factor: 508.702

6.  Comprehensive genomic profiles of small cell lung cancer.

Authors:  Julie George; Jing Shan Lim; Se Jin Jang; Yupeng Cun; Luka Ozretić; Gu Kong; Frauke Leenders; Xin Lu; Lynnette Fernández-Cuesta; Graziella Bosco; Christian Müller; Ilona Dahmen; Nadine S Jahchan; Kwon-Sik Park; Dian Yang; Anthony N Karnezis; Dedeepya Vaka; Angela Torres; Maia Segura Wang; Jan O Korbel; Roopika Menon; Sung-Min Chun; Deokhoon Kim; Matt Wilkerson; Neil Hayes; David Engelmann; Brigitte Pützer; Marc Bos; Sebastian Michels; Ignacija Vlasic; Danila Seidel; Berit Pinther; Philipp Schaub; Christian Becker; Janine Altmüller; Jun Yokota; Takashi Kohno; Reika Iwakawa; Koji Tsuta; Masayuki Noguchi; Thomas Muley; Hans Hoffmann; Philipp A Schnabel; Iver Petersen; Yuan Chen; Alex Soltermann; Verena Tischler; Chang-min Choi; Yong-Hee Kim; Pierre P Massion; Yong Zou; Dragana Jovanovic; Milica Kontic; Gavin M Wright; Prudence A Russell; Benjamin Solomon; Ina Koch; Michael Lindner; Lucia A Muscarella; Annamaria la Torre; John K Field; Marko Jakopovic; Jelena Knezevic; Esmeralda Castaños-Vélez; Luca Roz; Ugo Pastorino; Odd-Terje Brustugun; Marius Lund-Iversen; Erik Thunnissen; Jens Köhler; Martin Schuler; Johan Botling; Martin Sandelin; Montserrat Sanchez-Cespedes; Helga B Salvesen; Viktor Achter; Ulrich Lang; Magdalena Bogus; Peter M Schneider; Thomas Zander; Sascha Ansén; Michael Hallek; Jürgen Wolf; Martin Vingron; Yasushi Yatabe; William D Travis; Peter Nürnberg; Christian Reinhardt; Sven Perner; Lukas Heukamp; Reinhard Büttner; Stefan A Haas; Elisabeth Brambilla; Martin Peifer; Julien Sage; Roman K Thomas
Journal:  Nature       Date:  2015-07-13       Impact factor: 49.962

7.  Changes in the presentation of nodular and superficial spreading melanomas over 35 years.

Authors:  Melanie A Warycha; Paul J Christos; Madhu Mazumdar; Farbod Darvishian; Richard L Shapiro; Russell S Berman; Anna C Pavlick; Alfred W Kopf; David Polsky; Iman Osman
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

8.  Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.

Authors:  Jochen Jaeger; Dirk Koczan; Hans-Juergen Thiesen; Saleh M Ibrahim; Gerd Gross; Rainer Spang; Manfred Kunz
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

9.  Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites.

Authors:  Shigeki Sekine; Yukihiro Nakanishi; Reiko Ogawa; Satoko Kouda; Yae Kanai
Journal:  Virchows Arch       Date:  2009-03-25       Impact factor: 4.064

10.  NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

Authors:  Katarina Omholt; Anton Platz; Lena Kanter; Ulrik Ringborg; Johan Hansson
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

View more
  23 in total

Review 1.  Emerging strategies to treat rare and intractable subtypes of melanoma.

Authors:  Gretchen M Alicea; Vito W Rebecca
Journal:  Pigment Cell Melanoma Res       Date:  2020-04-24       Impact factor: 4.693

Review 2.  Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.

Authors:  Emanuelle M Rizk; Angelina M Seffens; Megan H Trager; Michael R Moore; Larisa J Geskin; Robyn D Gartrell-Corrado; Winston Wong; Yvonne M Saenger
Journal:  Am J Clin Dermatol       Date:  2020-02       Impact factor: 7.403

Review 3.  Genome-wide association studies and polygenic risk scores for skin cancer: clinically useful yet?

Authors:  M R Roberts; M M Asgari; A E Toland
Journal:  Br J Dermatol       Date:  2019-07-07       Impact factor: 9.302

4.  Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers.

Authors:  Clio Dessinioti; Niki Dimou; Alan C Geller; Aravella Stergiopoulou; Serigne Lo; Ulrike Keim; Jeffrey E Gershenwald; Lauren E Haydu; Simone Ribero; Pietro Quaglino; Susana Puig; Josep Malvehy; Lidija Kandolf-Sekulovic; Tatjana Radevic; Roland Kaufmann; Laura Meister; Eduardo Nagore; Victor Traves; Grigorios G Champsas; Mihaela Plaka; Brigitte Dreno; Emilie Varey; David Moreno Ramirez; Reinhard Dummer; Joanna Mangana; Axel Hauschild; Friederike Egberts; Ketty Peris; Laura Del Regno; Ana-Maria Forsea; Sabina A Zurac; Ricardo Vieira; Ana Brinca; Iris Zalaudek; Teresa Deinlein; Eleni Linos; Evangelos Evangelou; John F Thompson; Richard A Scolyer; Claus Garbe; Alexander J Stratigos
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

5.  Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy.

Authors:  R R Maniyar; S Chakraborty; T Jarboe; R Suriano; M Wallack; J Geliebter; R K Tiwari
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study.

Authors:  M Mandalà; P Rutkowski; F Galli; R Patuzzo; V De Giorgi; E Rulli; A Gianatti; B Valeri; B Merelli; A Szumera-Ciećkiewicz; D Massi; A Maurichi; P Teterycz; M Santinami
Journal:  ESMO Open       Date:  2022-04-11

Review 7.  Management of primary skin cancer during a pandemic: Multidisciplinary recommendations.

Authors:  Brian C Baumann; Kelly M MacArthur; Jerry D Brewer; William M Mendenhall; Christopher A Barker; Jeremy R Etzkorn; Nathaniel J Jellinek; Jeffrey F Scott; Hiram A Gay; John C Baumann; Farrin A Manian; Phillip M Devlin; Jeff M Michalski; Nancy Y Lee; Wade L Thorstad; Lynn D Wilson; Carlos A Perez; Christopher J Miller
Journal:  Cancer       Date:  2020-06-01       Impact factor: 6.860

8.  Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response.

Authors:  Monique K van der Kooij; Marjolein J A L Wetzels; Maureen J B Aarts; Franchette W P J van den Berkmortel; Christian U Blank; Marye J Boers-Sonderen; Miranda P Dierselhuis; Jan Willem B de Groot; Geke A P Hospers; Djura Piersma; Rozemarijn S van Rijn; Karijn P M Suijkerbuijk; Albert J Ten Tije; Astrid A M van der Veldt; Gerard Vreugdenhil; Michel W J M Wouters; John B A G Haanen; Alfonsus J M van den Eertwegh; Esther Bastiaannet; Ellen Kapiteijn
Journal:  Cancers (Basel)       Date:  2020-07-27       Impact factor: 6.639

9.  Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma.

Authors:  Paul Johannet; Nicolas Coudray; Douglas M Donnelly; George Jour; Irineu Illa-Bochaca; Yuhe Xia; Douglas B Johnson; Lee Wheless; James R Patrinely; Sofia Nomikou; David L Rimm; Anna C Pavlick; Jeffrey S Weber; Judy Zhong; Aristotelis Tsirigos; Iman Osman
Journal:  Clin Cancer Res       Date:  2020-11-18       Impact factor: 13.801

10.  Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients.

Authors:  Christoph Wohlmuth; Iris Wohlmuth-Wieser; Taymaa May; Danielle Vicus; Lilian T Gien; Stéphane Laframboise
Journal:  Am J Clin Dermatol       Date:  2020-04       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.